Madrigal Pharmaceuticals (MDGL) Receivables (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Receivables for 4 consecutive years, with $192.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Receivables rose 142.72% year-over-year to $192.3 million; the TTM figure through Jun 2026 stood at $192.3 million (up 142.72% YoY), while the FY2025 annual figure was $134.5 million, up 149.85% from the prior year.
• Receivables grew to $192.3 million in Q2 2026 per MDGL's latest filing, from $187.4 million in the prior quarter.
• Across five years, Receivables topped out at $192.3 million in Q2 2026 and bottomed at $6.9 million in Q2 2024.
• Historically, Receivables has averaged $95.5 million across 3 years, with a median of $79.2 million in 2025.
• Annual changes were most pronounced in 2025 — Receivables surged 1048.44% — and 2026, when it jumped 142.72%.
• Madrigal Pharmaceuticals' Receivables stood at $53.8 million in 2024, then soared by 149.85% to $134.5 million in 2025, then soared by 43.01% to $192.3 million in 2026.
• Business Quant data shows MDGL's Receivables at $192.3 million in Q2 2026, $187.4 million in Q1 2026, and $134.5 million in Q4 2025.